Skip Navigation

Annals of Oncology 2008 19(1):191; doi:10.1093/annonc/mdm530
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Torresi, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Torresi, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Trastuzumab-treated advanced breast cancer patients and brain metastases: just a little alert

The first 10% of the full text of this article appears below.

Recently, some authors reported the high frequency of localizations to the central nervous system (CNS) in HER-2-positive breast cancer patients [1]. There are three hypotheses to explain such phenomenon: (i) . . . [Full Text of this Article]

U. Torresi

Department of Oncology, Ospedale Macerata, Via Santa Lucia 2, 62100 Macerata, Italy

(E-mail: umberto57@comeg.it)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
I. H. Park, J. Ro, K. S. Lee, B. H. Nam, Y. Kwon, and K. H. Shin
Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
Ann. Onc., January 1, 2009; 20(1): 56 - 62.
[Abstract] [Full Text] [PDF]